Publications by authors named "An-Li Yu"

Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression. Nevertheless, how tafamidis alters clinical and imaging parameters remains unclear.

View Article and Find Full Text PDF

Background: To evaluate the correlation between atrial fibrillation (AF) burden and two-dimensional LA (left atrium) longitudinal reservoir strain (LARS) to explore the potential clinical utility of this novel parameter in patients with AF.

Methods: This cross-sectional study was conducted at the cardiac electrophysiology clinic of a tertiary centre by consecutively enrolling patients with non-valvular AF. The AF burden was evaluated using 14-day patch-based electrocardiography and defined as the percentage of time spent in AF during a 14-day monitoring period.

View Article and Find Full Text PDF

Objective: Tafamidis has shown potential in slowing disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate serial changes on [Tc]Tc-pyrophosphate (PYP) scintigraphy during tafamidis treatment for hereditary ATTR-CM.

Methods: We retrospectively analyzed a prospectively collected cohort of Ala97Ser (A97S) hereditary ATTR-CM patients treated with tafamidis (61 mg/day) and a control group comprising A97S hereditary ATTR-CM patients who had not received disease-modifying medications.

View Article and Find Full Text PDF
Article Synopsis
  • RNA interference (RNAi) therapeutics, specifically patisiran and vutrisiran, were studied for their effects on transthyretin amyloid cardiomyopathy (ATTR-CA) by analyzing SPECT/CT imaging outcomes.
  • Eight patients with hereditary ATTR-CA were monitored, with one group starting RNAi treatment alongside their first imaging, and another group being on treatment prior to imaging.
  • Findings revealed a significant decrease in a volumetric heart/lung ratio in patients receiving RNAi therapies, indicating potential benefits in managing ATTR-CA symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • Exercise intolerance is a common issue for patients with atrial fibrillation (AF), and this study sought to identify echocardiographic markers that could predict their exercise capacity.
  • The study involved 188 patients with AF who underwent echocardiography and cardiopulmonary exercise testing, finding that 71.2% had impaired exercise capacity, with specific echocardiographic features linked to this decline.
  • The left atrial to left ventricular end-diastolic diameter (LA/LVEDD) ratio emerged as a significant predictor of exercise capacity, suggesting its potential importance for patient management, although further research is needed.
View Article and Find Full Text PDF

Background: Transthyretin cardiomyopathy (ATTR-CM) is a debilitating disease that has received much attention since the emergence of novel treatments. The Transthyretin Cardiomyopathy Clinical Trial showed that tafamidis, a transthyretin tetramer stabilizer, effectively reduced the declines in functional capacity and quality of life. However, Ala97Ser (A97S) hereditary ATTR-CM is underrepresented in major ATTR-CM tafamidis trials.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a severe and progressive heart disease, and this study investigates how eplontersen therapy affects the monitoring of this condition using bone scintigraphy.
  • The research analyzed data from the NEURO-TTRansform trial, comparing patients taking eplontersen with a control group not on this treatment, and noted significant reductions in heart and lung volume ratios in those receiving eplontersen.
  • The results indicate that eplontersen may effectively treat hATTR-CM, and the use of technetium-99m-pyrophosphate imaging could be crucial for assessing treatment effectiveness.
View Article and Find Full Text PDF

Background: Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are unknown. This study aimed to used cardiac magnetic resonance (CMR) to investigate the effects of tafamidis on patients with hereditary A97S ATTR-CM.

View Article and Find Full Text PDF

Background: The main target of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the sodium-glucose cotransporters 2, is found in the kidneys, and their activity is reduced in patients with chronic kidney disease (CKD). How the efficacy of SGLT2i may vary in patients with different levels of renal impairment has not been fully elucidated.

Methods: We searched the PubMed databases for relevant studies published through May 25, 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious and progressive heart disease that can be deadly, with the A97S genetic mutation being the most prevalent in Taiwan.
  • This study focused on assessing the effectiveness of tafamidis, a medication that stabilizes transthyretin, in patients with the A97S subtype of ATTR-CM after 6 months of treatment.
  • Results revealed that after 6 months, patients showed a significant drop in NT-proBNP levels, indicating improved cardiac function, particularly among those with severe symptoms.
View Article and Find Full Text PDF

Wet beriberi is a rare but fatal disease in modern society. The nonspecific clinical manifestations, including symptoms of heart failure and recalcitrant lactic acidosis, can prevent timely diagnosis. The use of a pulmonary artery catheter can promptly confirm a high cardiac output state and plays a crucial role in rapidly deteriorating cases.

View Article and Find Full Text PDF

Aims/hypothesis: This study aimed to assess the real-world outcomes of people with diabetes mellitus treated with glucagon-like peptide-1 receptor agonists (GLP1RAs) compared with those treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) in terms of major adverse cardiovascular and limb events. Peripheral artery disease is a common cause of morbidity in people with diabetes. Previous cardiovascular outcome trials have demonstrated the benefits of GLP1RAs and SGLT2is for reducing various cardiovascular events, but the safety and efficacy of these drugs on limb outcomes remain subject to debate and ambiguity.

View Article and Find Full Text PDF

Objectives: The "obesity paradox" - in which patients with obesity exhibit superior survival than normal-weight counterparts - has been reported for several diseases. However, obesity is a well-known risk factor for cardiovascular disease, and whether the obesity paradox is present in peripheral artery disease (PAD) is unknown.

Methods: A comprehensive search for studies that reported mortality in patients with PAD grouped by BMI identified 12 studies.

View Article and Find Full Text PDF

Objective: Obesity is a significant risk factor for atherosclerotic cardiovascular disease; however, the "obesity paradox", in which obese patients enjoy superior survival, has been observed in various cardiovascular conditions. Whether this phenomenon exists for peripheral artery disease (PAD) remains uncertain. The goal of this study was to evaluate the relationship between body mass index (BMI) and mortality in patients with PAD.

View Article and Find Full Text PDF

Anther indehiscence is an important form of functional male sterility that can facilitate the production of hybrid seed; however, the molecular mechanisms of anther indehiscence-based male sterility have not been thoroughly explored in eggplant ( L.). Here, we used two-dimensional gel electrophoresis to compare the protein profiles in the anthers of normally developing (F142) and anther indehiscent (S16) plants.

View Article and Find Full Text PDF